Finasteride Market Analysis

  • Report ID: 2984
  • Published Date: Sep 09, 2025
  • Report Format: PDF, PPT

Finasteride Market Segmentation:

End-user Segment Analysis

Under the end-user segment, home care leads the segment and is anticipated to hold a share value of 62.9% by 2035. The sub-segment of home care will hold the greatest share among end users by 2035. According to the CDC report, outpatient and self-administered therapies are becoming more common treatments for BPH as well as hair loss among the population. The ease of long-term oral medication administration, along with growing prescription refills via online pharmacies, aids market growth. In addition, patient behavior in the post-pandemic era is inclined towards treatments undertaken at home and repeat e-prescription services. This shift aids a strong home care segment outlook, further complemented by digital health services and remote patient interaction.

Application Segment Analysis

In the application segment, androgenetic alopecia leads the segment and is anticipated to hold a share value of 58.7% by 2035. The sub-segment is expected to dominate the finasteride market by 2035, owing to the rising incidence of hair loss in men between the ages of 18 to 45. Moreover, growing usage of direct-to-consumer telehealth platforms and FDA approvals for oral treatments of hair loss have tremendously enhanced access. Generic finasteride tablets 1 mg have garnered widespread acceptance among patients and healthcare practitioners due to their cost efficiency and high therapeutic results.

Distributing Channel Segment Analysis

The specialty clinics subsegment is predicted to reach the largest share of the finasteride market during the forecasted period. These specialty centers have healthcare practitioners specializing in dermatology as well as urology. These places render focused treatment for conditions such as benign prostatic hyperplasia and androgenetic alopecia. In the current times, people are willing to have personalized care with modern diagnostic tools. This makes them a preferred place for patients looking for effective and specialized treatments. Moreover, the rise of telehealth platforms has further propelled the accessibility and appeal of specialty clinics, contributing to their anticipated dominance in the market.

Our in-depth analysis of the global finasteride market includes the following segments:  

Segment

Subsegments

Application 

  • Androgenetic Alopecia (Male Pattern Baldness)
  • Benign Prostatic Hyperplasia (BPH)
  • Others (off-label use)

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

End user 

  • Hospitals
  • Homecare
  • Specialty Clinics

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In 2026, the industry size of finasteride is estimated at USD 1.7 billion in size.

Finasteride Market size was valued at approximately USD 1.6 billion in 2025 and is projected to reach around USD 4.6 billion by the end of 2035, rising at a CAGR of approximately 7.5% during the forecast period, i.e., between 2026-2035.

The finasteride market in North America dominates the market and is expected to hold the market share of 40.9% by 2035.

The major players in the market are Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Mylan N.V. (Viatris Inc.), Cipla Ltd., Merck & Co., Inc. (MSD), Aurobindo Pharma Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals, Sandoz (Novartis Generics Division), Glenmark Pharmaceuticals, Zydus Lifesciences Ltd., Towa Pharmaceutical Co. Ltd., Apotex Inc., Daewoong Pharmaceutical, Biocon Ltd., Abbott Laboratories, Duopharma Biotech Berhad, Aspen Pharmacare.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos